Musk v. Altman week 2: OpenAI fires back, and Shivon Zilis reveals that Musk tried to poach Sam Altman

The Musk v. OpenAI trial is exposing conflicting accounts over OpenAI’s 2017 restructuring plans, Musk’s push for a for-profit arm, and alleged attempts to recruit Sam Altman to a Tesla AI lab. Musk is seeking to unwind OpenAI’s restructuring and as much as $134 billion in damages, while the case could affect OpenAI’s IPO path toward a valuation near $1 trillion. Testimony from Greg Brockman and Shivon Zilis also adds governance and conflict-of-interest scrutiny around OpenAI, Microsoft, Tesla, xAI, and related AI deals.

Analysis

The key market issue is not the courtroom theater; it is whether this dispute slows OpenAI’s path to a public listing and forces a governance reset that bleeds into Microsoft’s commercialization cadence. A drawn-out remedy process would likely widen the discount rate applied to frontier-AI cash flows, because investors will have to price not just model execution risk but also board-control, IP, and cap-structure uncertainty. That is modestly negative for MSFT in the near term because Azure/AI monetization remains a core pillar of the multiple, even if the direct exposure is diluted by the company’s scale.

Second-order, the trial strengthens the competitive case for xAI only if it can capitalize on narrative disruption and talent churn. But the testimony also underscores a structural weakness: Musk’s organizations are increasingly cross-linked, which raises execution risk, related-party scrutiny, and financing complexity just as the market is being asked to underwrite a very large future valuation. That makes TSLA less of a pure AI beneficiary than the headline suggests; any incremental AI optionality is offset by governance overhang and the possibility that investors demand a higher conglomerate discount.

The cleanest beneficiary is not a public ticker but private-market infrastructure tied to model training and deployment. If OpenAI’s fundraising or IPO timeline slips, scarce capacity providers and AI infrastructure vendors can retain pricing power because the buildout is still capital intensive and time-sensitive. That said, if the court signals Musk is likely to lose on standing or remedy, the market could quickly re-rate the legal risk out over a 1-3 month horizon.

Consensus may be overestimating the probability of an immediate strategic shock and underestimating the longer tail of governance reform. Even a plaintiff win may not unwind the commercial ecosystem already built around OpenAI; the more likely outcome is incremental constraints, not a hard reset. That means the best trades are relative-value expressions on uncertainty compression rather than outright directional bets on AI demand.

Key Decisions for Investors

• Short MSFT into the next 2-6 weeks versus a basket of large-cap software/infra names: thesis is not earnings impairment but higher governance/legal discount on AI monetization; target 3-5% downside vs 1-2% index beta if trial headlines worsen.
• Pair trade: long AI infrastructure beneficiaries with limited direct litigation exposure, short TSLA on a 1-3 month horizon. TSLA’s AI optionality is increasingly offset by conglomerate governance risk; aim for a 1:2 risk/reward using tight stop-loss above prior headline-driven highs.
• If available, buy short-dated downside protection on MSFT or TSLA around next testimony/closing-argument windows. Event vol should be underpriced relative to binary headline risk; structure for 2-4 week expiry to capture sharp repricing.
• Avoid adding to long GOOGL on a sympathy AI-race trade; this dispute is more likely to prolong capital intensity and regulatory scrutiny than create a clean competitive win. Better entry is after remedy clarity, not during the trial.
• Maintain watchlist on private AI infrastructure names tied to training and deployment capacity; any OpenAI fundraising delay is a relative tailwind for vendors with constrained supply. This is a better risk/reward than chasing headline AI beta in public equities.